Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement.
The Company is evaluating ADI-001 across six autoimmune indications. Patient enrollment is ongoing in the Phase 1 study of ADI-001 for the treatment of lupus nephritis (LN). Patient enrollment in SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy, and stiff person syndrome (SPS) is expected to be initiated in the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.